GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » Cyclically Adjusted PS Ratio

Heidelberg Pharma AG (LTS:0QW5) Cyclically Adjusted PS Ratio : 12.00 (As of May. 01, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG Cyclically Adjusted PS Ratio?

As of today (2025-05-01), Heidelberg Pharma AG's current share price is €3.00. Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2024 was €0.25. Heidelberg Pharma AG's Cyclically Adjusted PS Ratio for today is 12.00.

The historical rank and industry rank for Heidelberg Pharma AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0QW5' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.6   Med: 8.31   Max: 13.17
Current: 11.46

During the past years, Heidelberg Pharma AG's highest Cyclically Adjusted PS Ratio was 13.17. The lowest was 1.60. And the median was 8.31.

LTS:0QW5's Cyclically Adjusted PS Ratio is ranked worse than
72.19% of 507 companies
in the Biotechnology industry
Industry Median: 5.15 vs LTS:0QW5: 11.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Heidelberg Pharma AG's adjusted revenue per share data for the three months ended in Aug. 2024 was €0.026. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.25 for the trailing ten years ended in Aug. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Heidelberg Pharma AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Heidelberg Pharma AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Cyclically Adjusted PS Ratio Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 6.27 8.12 12.56 9.53

Heidelberg Pharma AG Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.42 9.53 10.62 10.12 10.20

Competitive Comparison of Heidelberg Pharma AG's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Heidelberg Pharma AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cyclically Adjusted PS Ratio falls into.


;
;

Heidelberg Pharma AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Heidelberg Pharma AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.00/0.25
=12.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2024 is calculated as:

For example, Heidelberg Pharma AG's adjusted Revenue per Share data for the three months ended in Aug. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Aug. 2024 (Change)*Current CPI (Aug. 2024)
=0.026/126.1978*126.1978
=0.026

Current CPI (Aug. 2024) = 126.1978.

Heidelberg Pharma AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201411 0.088 99.543 0.112
201502 0.053 99.217 0.067
201505 0.103 100.417 0.129
201508 0.036 100.617 0.045
201511 0.059 99.717 0.075
201602 0.040 99.317 0.051
201605 0.038 100.617 0.048
201608 0.014 101.017 0.017
201611 0.020 100.517 0.025
201702 0.035 101.217 0.044
201705 0.028 101.817 0.035
201708 0.036 102.617 0.044
201711 0.032 102.117 0.040
201802 0.022 102.317 0.027
201805 0.047 103.917 0.057
201808 0.036 104.517 0.043
201811 0.022 104.217 0.027
201902 0.038 103.817 0.046
201905 0.094 105.418 0.113
201908 0.086 106.018 0.102
201911 0.040 105.318 0.048
202002 0.052 105.618 0.062
202005 0.052 106.018 0.062
202008 0.138 106.018 0.164
202011 0.032 105.018 0.038
202102 0.012 107.018 0.014
202105 0.014 108.170 0.016
202108 0.009 109.118 0.010
202111 0.018 110.173 0.021
202202 0.021 111.754 0.024
202205 0.328 115.760 0.358
202208 0.095 116.709 0.103
202211 0.060 119.872 0.063
202302 0.044 121.454 0.046
202305 0.050 122.824 0.051
202308 0.048 123.878 0.049
202311 0.069 123.668 0.070
202402 0.028 124.511 0.028
202405 0.060 125.776 0.060
202408 0.026 126.198 0.026

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Heidelberg Pharma AG  (LTS:0QW5) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Heidelberg Pharma AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines